Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary peer-reviewed biomedical journal that reports new findings and cutting-edge concepts in both pharmacogenomics and personalized medicine under a single cover. CPPM is an accelerator for global personalized medicine and pharmacogenomics. Importantly, the journal provides a multi-disciplinary integrated platform from cell to society to address diagnostics and responsible pharmacogenomics applications in developing countries.
CPPM cooperates with the Ibero-American Network of Pharmacogenetics and the Pacific Rim Association for Clinical Pharmacogenetics and welcomes peer reviewed contributions from qualified authors in any global region including the Central and Latin American countries, Asia-Pacific and developing countries.
The Journal scope is defined by three inter-connected aims. First, we are interested in genomics/postgenomics biotechnologies and diagnostics that enable global personalized medicine science (including and beyond pharmacogenomics) as long as they explain person-to-person and population differences in disease susceptibility or response to a health intervention, and they can be mechanistically substantiated. Second, we approach personalized medicine as ‘personalized health interventions’ focusing primarily on drug therapy, but also other interventions such as nutrition, vaccines, surgical devices, emerging cell-based therapies that collectively contribute to healthcare. Third, we strive to integrate molecular and clinical investigation with public policy, global health diplomacy and social studies of biotechnology that collectively shape postgenomics future(s) and innovation trajectories in life sciences. Priority will be given to expert reviews/ mini-reviews and research articles that include original ideas and findings related to the journal scope and mandate.
William Zabala, Raquel Cruz, Manuel Barreiro-de Acosta, María Chaparro, Julián Panes, Ana Echarri, Maria Esteve, Daniel Carpio, Montserrat Andreu, Esther Garcia-Planella, Eugeni Domenech, Angel Carracedo, Javier P. Gisbert, Francisco Barros and on behalf of EIGA and ENEIDA investigators
Dr. Adrián LLerena M.D., Ph.D. is the Director of the Clinical Research Center in the University Hospital in Badajoz Spain. between 1989-1993 he did his post doc at Karolinska Institute Sweden focusing on Clinical Pharmacogenetics. He has published more than 170 peer reviewed papers and book chapters (h index 38 Google Schoolar). He served in different Scietific societies as IberoAmerican Society of Pharmacogenomics. He has been principal investigator in more than 30 national and european research projects. Currently he is Vicepresident of the Spanish Society of Pharmacogenetics and Pharmacogenomics and Vicepresident of the Spanish Society for Clinical Pharmacology.